Evidence quality and methodological safeguards continue to surface across clinical and translational research, with a focus on how data handling affects regulatory and scientific credibility. The FDA’s rejection of Capricor’s deramiocel for data integrity violations is the most direct signal, but it aligns with other cautionary findings across healthcare research—including reviews emphasizing the difficulty of translating preclinical signals and the need for rigorous biomarker frameworks. Several reports also call out interpretability and calibration gaps in AI-enabled clinical workflows, and others highlight that biomarkers or model outputs must be validated and interpreted carefully. For the biotech sector, the combined message is that both regulators and researchers are tightening scrutiny around data provenance, mechanistic clarity, and deployment-ready evidence. As programs move from bench to bedside, execution and verification—not just scientific novelty—appear to be determining success criteria.